UCB, a global biopharmaceutical company, announced new interim data from BE BRIGHT, an open-label extension trial to assess the long-term safety, tolerability and efficacy of bimekizumab, an investigational IL-17A and IL-17F inhibitor, in adults with moderate to severe plaque psoriasis.1,2 These results were presented today during a platform presentation at the 2021 American Academy of Dermatology Summer Meeting, Tampa, Florida, U.S.
August 7, 2021
· 12 min read
